product name Thalidomide
258.23
Formula
C13H10N2O4
CAS No.
50-35-1
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 52 mg/mL (201.37 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 2 mg/mL (7.74 mM)
Solubility (In vivo)
30% PEG400+0.5% Tween80+5% Propylene glycol: 5 mg/mL
Chemical Name
2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19415782
| Thalidomide must be metabolized by the liver to form an epoxide that may be the active teratogenic metabolite. Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when human monocytes are triggered with lipopolysaccharide and other agonists in culture. | |
|---|---|
| In Vivo | Thalidomide (200 mg/kg) results in an inhibition of the area of vascularized cornea of rabbits that ranged from 30% to 51% in three experiments with a median inhibition of 36%. |
| Animal model | |
| Formulation & Dosage | |
| References | [1] D Amato RJ, et al. Proc Natl Acad Sci U S A, 1994, 91(9), 4082-4085. |
